Trial Profile
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2021
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Mercaptopurine; Mesna; Methotrexate; Methotrexate; Methotrexate; Ofatumumab; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 09 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 21 May 2019 Planned End Date changed from 1 Mar 2022 to 30 Mar 2022.
- 21 May 2019 Planned primary completion date changed from 1 Mar 2022 to 30 Mar 2022.